The Missing Critical Piece to the COVID-19 + Variants Puzzle: Oral Therapies
The COVID-19 pandemic has gripped America and the world in a medical, social, and economic crises, ushering in lockdowns and leading to severe economic slowdown globally.
Multiple new tactics will be essential to prevent and treat COVID-19 as economies reopen. With the uncertain threats new COVID-19 variants pose, NED-260 COVID is unlike any other COVID-19 treatment in development. Used to treat COVID-19 infection, the oral format requires no cold chain management or clinical infrastructure, allowing patients to treat their disease comprehensively and safely at home. In addition, pre-clinical evidence supports the use of NED-260 COVID as an oral prophylaxis for infection prevention, a desirable alternative for those with vaccine hesitancy, those who are immune compromised, and those who lack access to vaccines.
Most experts suggest that 70-80% herd immunity will be required to stem the Pandemic. Despite efforts since early 2021 to increase vaccinations for SARS-CoV-2, only 5.9% of the global population is vaccinated, and 42.6% in the U.S. Without widespread vaccine or treatments in place, our health remains at risk as economies reopen.
A prophylactic and treatment is needed to ensure the safety of our communities, globally.
1Our World In Data, as of June 6, 2021